Facebook Twitter LinkedIn Google Plus RSS

Actavis shareholders approve Warner Chilcott acquisition proposals

By ,

Parsippany-based specialty pharmaceutical company Actavis announced today its shareholders have approved several proposals related to the company's acquisition of Warner Chilcott. The approvals were required under closing conditions for the acquisition, which is expected to close early in the fourth quarter.

The acquisition, first announced in May, consists of a $5 billion stock swap of 0.16 of an Actavis share for each Chilcott share, valuing the Chilcott shares at $20.08 each. Current Actavis leadership will oversee the resulting company, Actavis PLC.






More From This Industry

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy